- Home
- GLTO vs CING Comparison
GLTO vs CING Comparison
Compare GLTO & CING Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GLTO
- CING
- Stock Information
- Founded
- GLTO 2011
- CING 2012
- Country
- GLTO Denmark
- CING United States
- Employees
- GLTO N/A
- CING N/A
- Industry
- GLTO Biotechnology: Pharmaceutical Preparations
- CING Biotechnology: Pharmaceutical Preparations
- Sector
- GLTO Health Care
- CING Health Care
- Exchange
- GLTO Nasdaq
- CING Nasdaq
- Market Cap
- GLTO 23.7M
- CING 21.6M
- IPO Year
- GLTO 2020
- CING 2021
- Fundamental
- Price
- GLTO $16.82
- CING $3.65
- Analyst Decision
- GLTO
- CING Strong Buy
- Analyst Count
- GLTO 0
- CING 3
- Target Price
- GLTO N/A
- CING $32.67
- AVG Volume (30 Days)
- GLTO 3.4M
- CING 133.6K
- Earning Date
- GLTO 11-06-2025
- CING 11-13-2025
- Dividend Yield
- GLTO N/A
- CING N/A
- EPS Growth
- GLTO N/A
- CING N/A
- EPS
- GLTO N/A
- CING N/A
- Revenue
- GLTO N/A
- CING N/A
- Revenue This Year
- GLTO N/A
- CING N/A
- Revenue Next Year
- GLTO N/A
- CING N/A
- P/E Ratio
- GLTO N/A
- CING N/A
- Revenue Growth
- GLTO N/A
- CING N/A
- 52 Week Low
- GLTO $2.01
- CING $3.20
- 52 Week High
- GLTO $33.60
- CING $6.01
- Technical
- Relative Strength Index (RSI)
- GLTO 55.60
- CING 51.95
- Support Level
- GLTO $15.76
- CING $3.40
- Resistance Level
- GLTO $29.03
- CING $3.69
- Average True Range (ATR)
- GLTO 4.83
- CING 0.23
- MACD
- GLTO -0.52
- CING 0.03
- Stochastic Oscillator
- GLTO 43.02
- CING 81.82
About GLTO Galecto Inc.
Galecto Inc is a clinical-stage biotechnology company developing therapeutics designed to target the biological processes that lie at the heart of cancer and liver diseases. Its initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2, or LOXL2. Its product candidate GB0139 is for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, a life-threatening progressive fibrotic disease of the lung. Its product GB1211, a selective oral galectin-3 inhibitor for the treatment of fibrosis related to non-alcoholic steatohepatitis, or NASH, and GB2064, a selective oral inhibitor of LOXL2 that it initially plans to develop for the treatment of myelofibrosis.
About CING Cingulate Inc.
Cingulate Inc is a clinical-stage biopharmaceutical company utilizing its proprietary precision timed-release drug delivery platform to build and advance a pipeline of next-generation pharmaceutical products designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic area to use PTR technology to develop future product candidates.